Partnering Opens for RESI San Francisco: Early Stage Investors Flock to RESI to Meet Startups

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

San Francisco’s annual healthcare conference week starts in just over a month.  Already, hundreds of investors have signed up to attend RESI San Francisco – our largest event of the year, which serves as a dedicated venue for early stage investors to meet with startups in the biotech, medical device, diagnostic and digital health sectors.  While many of these investors cover multiple silos in their hunt for the most promising opportunities, we have highlighted some top investors in each of RESI’s core innovation sectors below.  Would you like to book up to 16 face-to-face meetings with investors on January 8th?  Register online to join us at RESI.

Confirmed Therapeutics Investors

Click to See More…

 

Confirmed Medical Devices Investors

Click to See More…

 

Confirmed Diagnostics Investors

Click to See More…

 

Confirmed Digital Health Investors

Click to See More…

 

Wait! There is Still Time to Apply to RESI Innovation Challenge. Deadline Tomorrow…Go for It!

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Senior Research Analyst, LSN

claire

There are several important dates related to RESI San Francisco 2019 this week. With yesterday’s RESI partnering system launch, there is no doubt that our largest event of the year is closely approaching. Another date to keep in mind is tomorrow, Friday, December 7th, as Friday is the last date we are accepting applications for the RESI SF Innovation Challenge.

As usual, we will be selecting 30 finalists who are working on innovative technologies with high potential to scale in global markets. The Innovation Challenge is open to all early-stage companies in the therapeutics, medical devices, diagnostics, and digital health sectors who are actively fundraising. We will also be selecting several tech hub constituents to participate in the West Coast Innovators’ Pitch Challenge from 1:00 – 2:30 pm, where companies will be able to pitch in front of a panel of established investor judges and receive constructive feedback.

We encourage all applicants to read our article on how to be successful in the RESI Innovation Challenge. There is not much time left to apply – interested applicants, please complete your online application through our application portal here or submit your PDF application and supplementary materials by sending them to RESI@lifesciencenation.com. We look forward to receiving your submissions!

 

AI in Healthcare: Investors Explore a Hot New Topic at RESI SF

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, VP of Investor Research, LSN

Artificial intelligence is widely seen as the new frontier of tech innovation, and many applications for the technology have been found in healthcare.  Scientist-entrepreneurs are exploring AI diagnostics, AI drug discovery, AI imaging analysis, AI for personalized medicine, and more.  At RESI San Francisco, a panel of investors who focus on this field will discuss how they see the risks and opportunities that are arising for AI in healthcare.

The panelists are:

  • Elaine Mo, Ascend Capital Partners
  • Edward Kliphuis, M Ventures
  • Armen Vidian, Data Collective
  • Lu Zhang, Fusion Fund
  • Yizhen Dong, 11.2 Capital

Panelists will discuss what they’re looking for when they evaluate an AI opportunity, what challenges (including regulatory) they see on the horizon, and where they see the real potential for AI technologies in health.  Join us at RESI to see this panel live.

 

Hot Investor Mandate: Healthcare Investment Firm Seeks to Invest Primarily in Breakthrough Oncology Therapeutics

~ Next Phase Admin ~ Leave a comment

A healthcare investment firm founded in 1992 with offices in the USA actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes.

The firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan Evergreen Fund Invests in Therapeutics, Devices, Diagnostics, and Digital Health Companies in Taiwan and North America

~ Next Phase Admin ~ Leave a comment

A healthcare-focused evergreen fund wholly owned by a large Taiwan corporate seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$1 to 5 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from Taiwan, the US, and Canada.

Within healthcare, the firm considers broadly across the healthcare field, including biomedicine, medical devices and diagnostics. The firm currently has an increased interest in digital health. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.

The firm is looking for competent and experienced management teams. As a well-networking Asia investor, the firm does not typically request regional rights, but can provide assistance with finding potential Asia partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: New York VC Firm Invests in Novel Oncology Therapeutics, Diagnostics, and Devices, Including Rare Cancers

~ Next Phase Admin ~ Leave a comment

A New York-based investment firm typically invests up to $6 million per investment with the ability to bring in additional LP side pocket money. The firm invests primarily in the USA but is also open to considering opportunities in Canada.

The firm only invests in oncology companies. Within the oncology field, the firm invests in proprietary technologies in therapeutics, diagnostics and devices, and is open to investing in any form of cancer (including rare cancers), but has a preference for investing in large market opportunities. The firm prefers to invest in companies that have attained proof of concept data in animals and have entered into human clinical trials.

The firm prefer to work with highly qualified, experienced management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Australian Family Office Invests in Early-Stage Therapeutics, Medtech, and Digital Health Companies with Clearly Established Developmental Pathways

~ Next Phase Admin ~ Leave a comment

A family investment vehicle based in Australia invests in early-stage life science and digital health startups. The firm is focused on the Australian and U.S. markets with directors of the fund present in both countries. The fund is flexible in terms of investment size and capital structure and may co-invest or lead financing rounds.

The firm is interested in therapeutics, medtech and digital health companies. The group has a preference for companies that have some clinical data and is most interested in indications where the science is well-understood and the development path is straight-forward. The fund is particularly interested in repurposed and orphan drugs as well as other de-risked/accelerated regulatory pathways. The firm is most interested in ophthalmology, dermatology, microbiome-related technologies, the premature infant space and orphan indications.

The firm has a strong preference for experienced management teams, and prefers companies with modest valuations and capital needs so that their investment is impactful.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.